Tandem (TNDM) Q1 2026 Earnings Transcript

Tandem Diabetes Care reported record Q1 sales of $247 million and more than 29,000 pump shipments, with gross margin expanding nearly 500 bps to 55% and adjusted EBITDA margin improving to about 1%. Management reaffirmed FY2026 guidance for $1.065 billion to $1.085 billion in sales and 56%-57% gross margin, while highlighting PayGo pharmacy expansion to 40% formulary coverage and multiple new product/regulatory catalysts. Offsetting the positives are ongoing infusion set supply shortages and a $3 million to $4 million Q2 international headwind tied to the go-direct transition.

Analysis

The key read-through is that Tandem is trying to re-rate from a hardware-cycle story into a distribution-and-margin story. The most important second-order effect is that the pharmacy transition lowers up-front friction for patients while shifting economics toward recurring supply revenue; that should improve conversion from MDI and increase lifetime value per user, but it also creates a near-term mix headwind because the company is intentionally trading some first-order revenue recognition for higher retention and better gross profit later.

The market likely underappreciates how much of the next 2-3 quarters will be driven by execution quality, not demand. Management is signaling that the U.S. growth algorithm now depends on three variables moving together: formulary expansion, physician workflow adoption, and supply normalization. The infusion-set shortage is the main tactical risk because it can mask underlying demand strength and create false negatives in model-driven expectations, especially if the company keeps smoothing shortages with substitution rather than letting the revenue gap show up cleanly.

A more interesting contrarian angle is that the real catalyst may not be the quarter itself but the product stack coming into the second half: Android access, pregnancy clearance, and eventual tubeless Mobi all broaden the addressable market without requiring a new pump category to be invented. If the pharmacy channel reaches enough scale by year-end, the stock could start to trade less like a cyclical medtech name and more like a platform with recurring revenue and structurally higher gross margin. The main failure mode is timing: if pharmacy ramp, direct Europe transition, and supply recovery all slip simultaneously, the market will focus on the near-term sales bridge rather than the strategic improvement.

Key Decisions for Investors

• Go long TNDM on a 3-6 month horizon; the setup favors multiple expansion if pharmacy mix and gross margin inflect together. Risk/reward is attractive if management keeps reaffirming FY26, but size modestly because the path depends on execution, not macro.
• Use a call spread in TNDM (3-6 month tenor) to express upside from pharmacy adoption and product launches while limiting downside from supply noise and quarterly volatility.
• Pair trade: long TNDM / short DXCM for the next 1-2 quarters if you want to express share gains from business-model transition rather than category growth. The thesis is that Tandem has more visible operating leverage, while Dexcom is more exposed to sentiment around incumbent growth normalization.
• If already long TNDM, hedge with short-dated puts into the next print until there is evidence the infusion-set issue is fading. The stock can easily re-trade on any supply-related miss before the margin story matters.
• Watch for a better entry after any Q2 guide-driven pullback; the cleanest catalyst window is late 2H26 when direct Europe, Android, and Mobi Tubeless can all contribute together.